Novartis, CH0012005267

Novartis stock falls as clinical setbacks weigh despite Cosentyx EU boost

Published on 09/20/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock has dropped about 10 percent over the past 30 days by September 20, 2026 after a series of late-stage clinical trial failures, even as Cosentyx wins a key EU opinion for polymyalgia rheumatica. The company still targets 5 to 6 percent annual net sales growth through 2030 and confirmed its full-year 2026 guidance after second-quarter results.

Pop-Art-Illustration einer DNA-Doppelhelix mit Kapsel in leuchtendem Halftone-Raster — Novartis AG CH0012005267 – Pop-Art-Comic mit stilisierter DNA-Helix und Kapsel im bunten Halftone-Raster, Illustration mit AI erstellt.

Novartis stock (ISIN CH0012005267) is trading around 15 percent below its 52-week high as of September 20, 2026, after a sharp pullback driven by a cluster of clinical trial setbacks, even though the company has just secured a positive EU opinion for Cosentyx in polymyalgia rheumatica according to a recent analysis published on September 20, 2026.

Pipeline setbacks drive recent share price decline

According to Ad-hoc-news on September 20, 2026, Novartis shares closed the latest session at EUR 122.44 on their European listing, leaving the stock down about 10 percent over the past 30 days and roughly 15 percent below its 52-week high of EUR 144.30.

The same report highlights that the selloff followed what it describes as the steepest single-day share price drop in the company’s history after del-desiran, a late-stage candidate in myotonic dystrophy type 1, missed its primary endpoint in the Phase 3 HARBOR study, undermining expectations that the asset acquired through the Avidity Biosciences transaction would become a growth driver.Ad-hoc-news The article notes that this was only one in a string of setbacks: in early September, pelacarsen failed to significantly reduce cardiovascular events versus placebo in the Phase 3 Lp(a)HORIZON trial, even though it lowered lipoprotein(a) levels, and a few days later Novartis paused eight studies of an experimental cell therapy after patient deaths in late August.

Further pressure came when Novartis terminated development of an ALS candidate VHB937 (lifonebart) after it missed both primary and secondary endpoints in the Phase 2 ASTRALS study, marking the fourth clinical disappointment within weeks and reinforcing investor concerns about R&D productivity.Ad-hoc-news These cumulative events explain much of the recent underperformance of Novartis stock relative to its own 52-week range.

Cosentyx EU opinion and core portfolio provide support

Despite the setbacks, the same September 20, 2026 coverage reports that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for Cosentyx (secukinumab) in polymyalgia rheumatica, positioning it to become the first IL-17A inhibitor approved for this indication in Europe if the European Commission confirms the recommendation.Ad-hoc-news For investors, this adds a potential new revenue stream from an already established autoimmune franchise, partly offsetting disappointment from experimental programs.

The report also notes that in the second quarter of 2026 Novartis relied heavily on established medicines such as Kisqali, Kesimpta, Scemblix and Pluvicto, which delivered momentum and helped the company confirm its full-year 2026 guidance.Ad-hoc-news While the article does not quote exact second-quarter revenue or profit figures, it emphasizes that these key brands contributed enough to underpin management’s confidence in meeting the 2026 outlook, which remains a crucial anchor for valuation after the trial disappointments.

Looking beyond 2026, Novartis continues to target net sales growth of 5 to 6 percent annually through 2030, a goal it reiterated despite the recent pipeline turbulence.Ad-hoc-news For shareholders, the tension between these medium-term growth ambitions and short-term R&D setbacks is now central: the more the marketed portfolio can grow and expand into new indications like polymyalgia rheumatica, the more room the company has to absorb failures elsewhere in its pipeline.

Risk perception and stock positioning

Market commentary in recent days has highlighted how concentrated clinical news can quickly reshape risk perception around a large pharmaceutical group like Novartis, with several setbacks in a short period challenging confidence in the development portfolio even as commercial franchises remain strong.Ad-hoc-news The roughly 10 percent share price decline over the past month and the 15 percent gap to the 52-week high quantify that shift in sentiment, suggesting that investors are demanding clearer evidence that upcoming trials and indications can deliver more consistent success.

From an investor perspective, the current setup therefore combines one quantified negative factor and one positive offsetting element: on the one hand, four reported clinical failures and pauses within weeks have led to a double-digit price retreat; on the other hand, the CHMP’s positive opinion for Cosentyx in polymyalgia rheumatica and the second-quarter 2026 confirmation of guidance show that the marketed portfolio is still delivering and that management is not revising its 5 to 6 percent annual net sales growth target through 2030.Ad-hoc-news How the balance between these opposing forces evolves will likely depend on the next wave of data and regulatory decisions, including the European Commission’s final ruling on Cosentyx.

Stock level and market context

In the latest trading session referenced on September 20, 2026, Novartis shares on their European listing closed at EUR 122.44, compared with a 52-week high of EUR 144.30, putting the stock approximately 15 percent below that high and quantifying the recent pullback against its own historical range.Ad-hoc-news For investors following the stock, this level reflects both the discount the market is applying for pipeline uncertainty and the support coming from established medicines and a growing autoimmune franchise.